TY - JOUR T1 - Lutein and zeaxanthin supplementation in preterm infants to prevent retinopathy of prematurity: a randomized controlled study. JF - J Matern Fetal Neonatal Med Y1 - 2012 A1 - Dani, Carlo A1 - Lori, Ilaria A1 - Favelli, Federica A1 - Frosini, Saverio A1 - Messner, Hubert A1 - Wanker, Petra A1 - De Marini, Sergio A1 - Oretti, Chiara A1 - Boldrini, Antonio A1 - Massimiliano, Ciantelli A1 - Bragetti, Patrizia A1 - Germini, Cristiana KW - Antioxidants KW - Drug Administration Schedule KW - Drug Combinations KW - Female KW - Humans KW - Infant, Newborn KW - Infant, Premature KW - Logistic Models KW - Lutein KW - Male KW - Retinopathy of Prematurity KW - Risk Factors KW - Treatment Outcome KW - Xanthophylls KW - Zeaxanthins AB -

OBJECTIVES: Lutein and its isomer zeaxanthin (L/Z) function in the eye as antioxidant agents and blue-light filters. Our aim was to evaluate whether their administration could help decrease the occurrence of retinopathy of prematurity (ROP) in preterm infants.

METHODS: Infants with gestational age ≤32 weeks were randomly assigned to receive a daily dose of L/Z (0.14 + 0.006 mg) or placebo until discharge.

RESULTS: ROP occurrence was similar in the L/Z (11/58; 19%) and placebo (15/56; 27%) groups, as the occurrence of ROP at each stage and the need of eye surgery.

CONCLUSION: L/Z supplementation was ineffective in preventing ROP in preterm infants and did not affect the outcome at discharge of our patients.

VL - 25 IS - 5 U1 - http://www.ncbi.nlm.nih.gov/pubmed/22003960?dopt=Abstract ER -